A clinical study of Japanese head and neck squamous cell carcinoma patients treated with radiotherapy and cetuximab

DOI Web Site 1 Citations 7 References
  • Koshizuka Keiichi
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine
  • Arimoto Syohei
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine
  • Yamasaki Kazuki
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine
  • Chazono Hideaki
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine
  • Hanazawa Toyoyuki
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine
  • Okamoto Yoshitaka
    Department of Otorhinolaryngology/Head and Neck Surgery, Chiba University Graduate School of Medicine

Bibliographic Information

Other Title
  • 当科における頭頸部癌に対するセツキシマブ併用放射線治療40例の治療経験

Search this article

Description

In Japan, the treatment of head and neck squamous cell carcinoma (HNSCC) has changed because of the use of cetuximab. Particularly, radiotherapy with cetuximab (bioradiotherapy, BRT) has a high cure rate and is now a treatment option for HNSCC. However, there are few reports regarding the use of BRT in Japanese patients, and standard criteria for choosing between BRT and chemoradiotherapy with platinum are not available. We report the primary outcome of BRT for HNSCC patients in our department. <br>Forty HNSCC patients who underwent BRT between May 2013 and May 2014 were retrospectively evaluated. Most of the patients, including those with oropharyngeal, hypopharyngeal, and laryngeal cancer, had cancer progression. All patients underwent BRT following the protocol of the Bonner trial. The average follow-up duration was 15.8 months (range, 1–24 months). The response rate was 94.9%, including 70% of patients with a complete response and 22.5% of patients with a partial response. The BRT completion rate was 79.8%; however, eight patients discontinued BRT. We were able to shorten the length of hospital treatment by providing outpatient BRT.<br>For reasons of the high completion rate and response rate, we consider BRT to be a useful treatment. Moreover, it is necessary to consider how to use BRT and chemoradiotherapy with platinum; further long-term and large-scale studies are needed.

Journal

  • Toukeibu Gan

    Toukeibu Gan 42 (1), 81-86, 2016

    Japan Society for Head and Neck Cancer

Citations (1)*help

See more

References(7)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top